OncoMatch/Clinical Trials/NCT05173272
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
Is NCT05173272 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Neoadjuvant Therapy for cervical cancer.
Treatment: Neoadjuvant Therapy — The main objective of this study is to determine whether neoadjuvant chemotherapy combined with slulimumab sequential concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced cervical cancer could improve progression-free survival rates. Women in the experimental arm will receive neoadjuvant chemotherapy (cisplatin plus paclitaxel) combined with slulimumab every 21 days during 2 cycles followed by concurrent chemoradiation therapy. Women in the control arm will receive concurrent chemoradiation therapy alone. 286 patients will be recruited during 2 years, with 3 years of follow up period.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage FIGO 2018 IB3, FIGO 2018 II, FIGO 2018 IIIA, FIGO 2018 IIIB, FIGO 2018 IIIC1, FIGO 2018 IIIC2 (FIGO 2018)
FIGO 2018 Ib3-IIIc2
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC1.5d710^9/L, platelet count100d710^9/L, Hb90g/L, WBC3.0d710^9/L, and no bleeding tendency
Kidney function
Serum creatinine (Cr) 1.5 d7 ULN or endogenous creatinine clearance 50mL/min
Liver function
Total bilirubin (TBIL)1.5d7ULN (Gilbert syndrome allows 5d7ULN); ALT and AST 142.5d7ULN
Cardiac function
left ventricular ejection fraction (LVEF) 50%
No obvious signs of hematological diseases, ANC1.5d710^9/L, platelet count100d710^9/L, Hb90g/L, WBC3.0d710^9/L, and no bleeding tendency before enrollment; Adequate hepato-renal function is needed, including: Total bilirubin (TBIL)1.5d7ULN (Gilbert syndrome allows 5d7ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 142.5d7ULN Serum creatinine (Cr) 1.5 d7 ULN or endogenous creatinine clearance 50mL/min; Cardiac Function: left ventricular ejection fraction (LVEF) 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify